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We explored the additive effect of titrated oral theophylline in patients with stable
chronic obstructive pulmonary disease (COPD) who received both tiotropium, 18 mg od, and
formoterol, 12 mg bid. Thirty-six patients with moderate-to-severe COPD were enrolled in
this two-period trial. They were initially treated with formoterol+tiotropium for 4 weeks.
After this first period, they were divided in two groups of 18 patients. Both groups
continued with the initial treatment for further 4 weeks, but the first group received also
placebo whereas the second group received oral theophylline. The combination therapy
with formoterol+tiotropium induced a significant improvement in mean predose FEV1 and
FVC at the end of the first period, and a significant reduction in dyspnea score as measure
by a visual analogic scale and in use of rescue salbutamol. The second period of treatment
elicited a significant further improvement in lung function and reduction in dyspnea score
and salbutamol use in both groups. On the contrary, differences in improvements in FEV1
and FVC and reduction in dyspnea score and salbutamol use between theophylline and
placebo arms at the end of the second treatment period were not significant, although 5
patients reported an important relief in dyspnea during the theophylline administration
period. These findings question the importance of adding theophylline in stable COPD
patients already treated with two long-acting bronchodilators, but also indicate the
possibility that some of them can benefit from theophylline because of a symptomatic
improvement.
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
.it (M. Cazzola).
Internal Medicine, Unit of
e Tor Vergata, Rome, Italy.Introduction
Current evidence supports the recommendation of the
Global Initiative for chronic obstructive lung disease (GOLD)
guidelines1 and American Thoracic Society/European
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classes of long-acting inhaled bronchodilators, either once-
daily tiotropium or twice-daily salmeterol or formoterol, as
initial maintenance therapy for symptomatic chronic ob-
structive pulmonary disease (COPD). There is no data
supporting the superiority of one of the families of inhaled
bronchodilators (i.e., b2 agonists and anti-cholinergic
agents) over the other. Thus, the choice has to be based
on the individual symptomatic response. In patients who do
not respond satisfactorily to tiotropium or a long-acting
inhaled b-agonist as the initially prescribed single main-
tenance agent, the GOLD guidelines recommend the addi-
tion of the alternate class of long-acting inhaled
bronchodilator as the next step. In effect, an increasing
body of evidence3–7 indicates that the combination of a
long-acting b2-agonsit and a long-acting anti-muscarinic
agent is an effective therapeutic approach for patients
suffering from moderate-to-severe COPD.
Unfortunately treatments prescribed for COPD patients
do not always follow current guidelines, particularly in the
primary care setting. Recently, Taskin et al.8 have examined
the adherence to GOLD guidelines recommendation among
patients entering UPLIFT, a global trial evaluating the
efficacy of tiotropium in slowing COPD progression and have
observed that the percentage of patients receiving long-
acting bronchodilators increased as COPD severity in-
creased; however, a substantial number of patients were
not receiving long-acting bronchodilators in accordance with
GOLD guidelines. In particular, long-acting bronchodilators
(anti-cholinergics and/or b-agonists) were used in 67.3% and
69.3% of patients. The use of theophylline in 34.9% and
36.1% patients suffering from severe and very severe COPD,
respectively, was another unexpected finding.
Theophylline, which used to be part of the mainstay of
treatment for COPD, has been relegated to third-line
therapy in COPD because of the frequency of side effects
and relative low efficacy.9 Nonetheless, it is inexpensive and
still has its role. In fact, theophylline tends to be added to
these inhaled bronchodilators in more severe patients and
has been shown to give additional clinical improvement
when added to a long-acting b2-agonist.
10,11 Moreover,
increasing evidence shows that theophylline has significant
anti-inflammatory effects in COPD at lower plasma concen-
trations.12 In particular, Barnes12 has highlighted that it is
the only therapy currently available that is anti-inflamma-
tory in patients with COPD.
These findings are important and might justify the body of
evidence that supports the use of theophylline together with a
b2-agonist and an anti-cholinergic because a number of
patients with COPD may respond subjectively to theophylline.
In effect, GOLD guidelines1 report that the combination of a
b2-agonist, an anti-cholinergic, and theophylline may produce
additional improvements in lung function and heath status.
We examined the additive effect of oral theophylline in
patients with stable COPD who received both tiotropium,
18 mg od, and formoterol, 12 mg bid in a regular manner.Patients and methods
Thirty-six patients with well-controlled moderate-to-very
severe COPD were enrolled. All of them were 50 years of ageor older, and were current or former smokers with a 20 pack-
year or more history. Inclusion criteria required a baseline
FEV1 of less than 70% of predicted but more than 0.50 L, and
a postbronchodilator FEV1/FVC o70% following salbutamol,
400mg. Exclusion criteria were as follows: current evidence
of asthma as primary diagnosis; unstable respiratory disease
requiring oral/parenteral corticosteroids within 4 weeks
prior to beginning the study; upper or lower respiratory
tract infection within 4 weeks of the screening visit;
unstable angina or unstable arrhythmias; concurrent use of
medications that affected COPD or interacted with methyl-
xanthine products, such as macrolides or fluoroquinolones;
and evidence of alcohol abuse. All patients were not taking
theophylline at the time of recruitment in order to avoid the
well-known effects of theophylline withdrawal in COPD.13
Table 1 outlines some characteristics and the smoking
history of the population studied.
This was a single-blind, placebo-controlled, randomized,
two-period trial. Following an initial screening visit, all
eligible patients entered a 7 days inhaled placebo run-in
during which their regular treatment for COPD was stopped
and they received salbutamol for relief of breakthrough
symptoms and inhaled corticosteroids when already used.
Thereafter, all patients were treated with formoterol 12 mg
bid+tiotropium 18 mg od for 4 weeks. After this first period,
they were divided in two groups of 18 patients each in a
random manner. Both groups continued with the initial
treatment for further 4 weeks, but the first group also oral
received placebo twice whereas the second group received
oral theophylline (i.e., 200 or 300mg twice daily throughout
the 4 weeks [the 300-mg dose was only for patients
weighing480 kg, and these patients received 200mg bid
for first week and the higher 300-mg dose bid for the
remaining 3 weeks]). The patients were blinded to the
nature of the oral medications.
After the initial screening visit, patients returned to the
clinic at the end of the 7-day placebo run-in period for visit
2, at which time they started the treatment regimen with
formoterol+tiotropium. Afterwards, they attended the clinic
after 4 weeks of treatment when they were randomized to
placebo or theophylline, and after 4 further weeks of
treatment for evaluations of pulmonary function. Patients
withheld from taking their study medication on the morning
of each visit, so all measurements were made at trough
(i.e., approximately 12 h after their preceding evening dose
was received). At each visit, three FEV1 and FVC measure-
ments were taken, and the highest of each was recorded.
Changes in the perception of dyspnea assessed through use
of a bipolar visual anagogic scale (VAS), and supplemental
salbutamol use were also monitored at each visit. The VAS
consisted of a 20-cm horizontal line scoring between 0 (very
much better) at the left end, and 10 (very much worse) at
the right, with ‘no change’ in the middle. All patients were
familiarized with the VAS before the study. The supple-
mental salbutamol use was recorded by the patient daily
throughout the 2-month treatment period. At the end of the
second 4-week-treatment, we checked the serum theophyl-
line concentration in all patients included in the theophyl-
line arm.
Adverse events were collected through non-specific
questioning or direct observation by investigators at each
clinic visit and through spontaneous reports by patients.
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Table 1 Demographics of the population studied.
Variables Placebo arm Theophylline arm
Age (year) 63.873.1 66.274.0
Sex (no.) 15 M–3 F 17 M–1 F
Smoking (pack-year) 4874.7 5575.2
Current smokers, n (%) 12 (72) 11 (61)
FEV1, predicted (%) 42 (1.7) 39 (1.4)
FEV1/FVC ratio (before bronchodilator) 5073.2 5173.7
Inhaled corticosteroid use, n (%) 9 (50) 11 (61)
Tiotropium use, n (%) 7 (39) 6 (33)
Long-acting b2-agonist use, n (%) 18 (100) 18 (100)
Theophylline use, n (%) 2 (11) 1 (6)
Data are presented as mean7SE unless otherwise indicated. M, male; F, female.
Effect of theophylline on a combination of formoterol and tiotropium in stable COPD 959Patients who experienced exacerbation resulting in hospi-
talization or, at least, treatment with an oral corticosteroid
and/or antibiotic during the study period were withdrawn.
The definition of exacerbation used in the present study was
‘‘a worsening of respiratory symptoms, which requires
treatment with oral corticosteroids or antibiotics, or
both’’.14
This was a pilot study and the first known evaluation of
the additive effect of theophylline on a combination of
formoterol and tiotropium in stable COPD. In view of the
lack of previous experiences, no statistical hypotheses were
drawn and consequently no formal sample size calculation
was made. The use of a pilot study such as the current study
in clinical research is a well-established scientific procedure
and only through the use of a pilot study can statisticians
clarify data distributions and determine appropriate sample
sizes for full-scale clinical trials.3
The primary efficacy measure was the mean change from
baseline in predose FEV1 at the end of the study. Secondary
efficacy measures included change from baseline in FVC, VAS
score assessing dyspnea and in supplemental salbutamol.
Student’s t-test for paired data and repeated ANOVA
measurements were used for statistical analysis. Values of
po0:05 were considered as significant.Results
All patients completed the first treatment period with
formoterol+tiotropium. Thirty-three patients completed the
second treatment period: 17 patients in the placebo arm,
and 16 patients in the theophylline arm. The patient in the
placebo arm was withdrawn for COPD exacerbation resulting
in hospitalization. The two patients in the theophylline were
withdrawn for severe headache and rhythm disturbances,
respectively. There was no significant difference among the
post run-in baseline spirometric values of the two treatment
groups (FEV1, P40.05)).
The mean7SE baseline FEV1 and FVC at the start of the
treatment periods were 1.01770.07 L and 1.99270.130 L,
respectively in the placebo arm and 0.94170.07 L and
1.86470.129 L, respectively, in the theophylline arm. Mean
predose FEV1 and FVC values significantly (Po0.001)
improved compared to baseline at the end of the first 4-
week treatment in both arms (Fig. 1). At the end of thesecond 4-week treatment, FEV1 (Po0.001 both in the
placebo arm and in the theophylline arm, respectively)
and FVC (Po0.05 in the placebo arm and Po0.001 in the
theophylline arm, respectively) values further significantly
improved in both arms (Fig. 1). On the contrary, differences
in improvements in FEV1 and FVC between theophylline and
placebo arms at the end of the second treatment period
were not significant (P ¼ 0.779 and P ¼ 0.638, respec-
tively).
The initial 4-week treatment with formoterol+tiotropium
induced a significant (Po0.001) improvement in dyspnea
and induced a significant (Po0.001) reduction in the use of
supplemental salbutamol (Fig. 2). At the end of the second
4-week treatment with formoterol+tiotropium, we observed
an additional significant improvement in dyspnea (Po0.01 in
the placebo arm and Po0.001 in the theophylline arm,
respectively) and a further significant (Po0.05, both in the
placebo arm and in the theophylline arm) reduction in the
use of salbutamol as rescue medication (Fig. 2). Differences
in changes in dyspnea score and use of supplemental
salbutamol between theophylline and placebo arms at the
end of the second treatment period were not significant
(P ¼ 0.436 and P ¼ 0.975, respectively). In any case, 5
patients reported an important relief in dyspnea at the end
the theophylline administration period.
Ten out of 16 patients had a theophylline concentration
above the lower limit of 10 mg/mL, only one had a serum
theophylline concentration 420 mg/mL, and in the other
five patients theophylline concentration was in the 7–10 mg/
mL range.
A part the three patients that were withdrawn for severe
adverse events, two patients in the theophylline arm
suffered from a mild gastrointestinal adverse event and
another from insomnia.Discussion
Theophylline is still widely used as a bronchodilator in COPD,
although inhaled bronchodilators are preferred.1,2 Usually
theophylline tends to be added to these inhaled broncho-
dilators in patients with more severe COPD.15 In a crossover
study, 16 patients with severe COPD received high-dose
salbutamol followed by high-dose theophylline, and the
opposite regimen.16 The increase in FEV1 with salbutamol
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Figure 2 Mean VAS score and daily numbers of puffs of
salbutamol as rescue medication averaged over the 7 days of
the run-in period (time point 0) and over the week preceding
each visit, during 8 weeks of therapy with formoterol 12 mg
bid+tiotropium 18mg od plus, in the second 4-week treatment,
placebo (n 17, squares) or theophylline (n 16, triangles),
respectively. Values are mean7SE. po0:001 vs. time point
0; yPo0:05, yyPo0:01 and yyyPo0:001 vs. 4-week time point.
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Figure 1 Mean FEV1 and FVC values during 8 weeks of therapy
with formoterol 12 mg bid+tiotropium 18mg od plus, in the
second 4-week treatment, placebo (n 17, squares) or theophyl-
line (n 16, triangles), respectively. Values are mean7SE.
Po0:001 versus time point 0 (end of the run-in); yPo0:05,
and yyyPo0:001 vs. 4-week time point.
M. Cazzola, M.G. Matera960alone was 24% of the baseline value, versus 17% with
theophylline alone. The responses to the two agents were
additive regardless of which drug was given first. Interest-
ingly, patients with reversibility to salbutamol showed a
large increase in FEV1 when theophylline was added (32% of
baseline), whereas those with poorly reversible obstruction
showed no additional benefit when theophylline was added.
These observations raise the question of the risk–benefit
ratio of theophylline therapy for patients with poorly
reversible obstruction. Others have recommended the
opposite: that theophylline must be reserved for patients
with bronchodilator irreversibility.17 Interestingly, many
studies have shown that combinations of b2-agonists, anti-
cholinergic agents, and theophylline can achieve additional
improvements in lung function and health status.18–20
Nonetheless, Lefcoe et al.21, who compared the bronchodi-
lator effects of ipratropium 40 mg plus oral fenoterol
5mg, plus oral oxtriphylline 400mg, and ipratropium
40 mg, plus fenoterol 5mg, plus oxtriphylline 400mg in a
double-blind, single-dose study of 15 bronchitis patients,
documented that the three-drug and the fenoterol–oxtri-
phylline regimens were not significantly better than ipra-
tropium alone.More recently, theophylline has been shown to give
additional clinical improvement when added to salmeter-
ol,10,11 but Yildiz et al.22 have documented that the addition
of theophylline to formoterol had similar effects on St.
George’s Respiratory Questionnaire scores and lung functions
when compared to formoterol+ipratropium. It has also been
reported that the combined use of theophylline with inhaled
tiotropium bromide produces better exercise capacity than
the tiotropium alone in patients with stable COPD.23
Our study documented that the addition of theophylline
on a combination of formoterol and tiotropium in stable
COPD did not induced a significant further improvement in
lung function and in dyspnea. We must underline that this
was a pilot study and, consequently, associated with an
insufficient statistical power. It is likely that the failure to
show a statistically significant difference between treat-
ments when we explored the impact of different therapies
on dyspnea and salbutamol use was likely associated with an
insufficient statistical power in the study, although the
differences between treatments were small. Obviously,
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lack of significance that we have repeatedly observed24 and,
perhaps, a study with a larger sample would likely have
reached statistical significance.
In any case, our study questions the importance of adding
theophylline in stable COPD patients already treated with
two long-acting bronchodilators, although it indicates the
possibility that some of them can benefit from theophylline
because of a symptomatic improvement. A systematic
review and meta-analysis of efficacy of theophylline in
people with stable COPD has documented that beneficial
effects may be obtained in individuals who remain sympto-
matic from COPD, despite first-line bronchodilator ther-
apy.25 We cannot confirm this finding because we have
observed improvement in dyspnea in both groups, but
differences between theophylline and placebo groups were
not significant. In any case, the fact that five patients
reported an important relief in dyspnea during the theophyl-
line administration period and these patients were between
those with more severe dyspnea at the end of the first
4-week treatment with formoterol+tiotropium supports this
opinion.
It is evident that larger parallel, randomized-controlled
trials with explicit clinical and diagnostic criteria, sufficient
duration of follow-up and description of all relevant clinical
outcome measures are warranted in order to understand
when the addition of theophylline is really needed. In any
case, theophylline possesses anti-inflammatory and immu-
nomodulatory effects in addition to its well-recognized
effects as a bronchodilator when administered at doses that
are not associated with unacceptable side effects and which
may be used in selected patients without serum monitor-
ing.26,27 Therefore, we believe that a combination therapy
with tiotropium and a long-acting b2-agonist may serve as a
basis for improved ‘triple therapy’ combinations with low-
dose theophylline with the aim of delivering three com-
plementary therapeutic effects for patients with COPD. In
order to explore this possibility, a trial of longer duration (at
least 1 year) is mandatory.References
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